Physician profile
Gregory Gibson
NPI 1831536747
$2,791.98
in general payments reported to CMS, 2019-2025
17 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $44.60 · 2021: $719 · 2022: $753 · 2023: $389 · 2024: $279 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,055.68 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Heartmate Touch, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.89 | 2021-2025 | Jardiance |
| Pfizer INC. | $206.93 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.09 | 2022-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $148.77 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $145.10 | 2023-2025 | Optimizer, Optimizer |
| Endotronix, INC. | $103.73 | 2021 | |
| One Lambda, INC. | $100.61 | 2024 | |
| Medtronic Vascular, INC. | $100.31 | 2019 | |
| Abiomed | $100.16 | 2025 | |
| Amgen INC. | $75.85 | 2022-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $64.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $58.74 | 2019 | |
| United Therapeutics Corporation | $45.55 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $44.60 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $22.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.48 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.